
    
      Background: postoperative recurrence after liver transplantation is a global problem, and
      there is no standard treatment model for postoperative recurrence. Objective: to select
      patients diagnosed with hepatocellular carcinoma (HCC) after liver transplantation and unable
      to receive local treatment, and to give sorafenib combined with realgar-indigo naturalis
      formula until the disease progression or the patient die or is lost to follow-up. To analyze
      the safety, efficacy and pharmacokinetic characteristics of sorafenib combined with compound
      huangdai tablets in patients with recurrent hepatocellular carcinoma after liver
      transplantation
    
  